GlaxoSmithKline Plc has paid €250 million in cash for the Switzerland-based vaccine company, Okairos AG, which has developed technology applicable to both prophylactic and therapeutic vaccine products. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
